{"id":60137,"date":"2024-02-28T06:35:09","date_gmt":"2024-02-28T06:35:09","guid":{"rendered":"https:\/\/medsname.com\/psyquit\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"psyquit","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/psyquit\/","title":{"rendered":"Psyquit"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Psyquit?<\/h3>\n
\n

Psyquit<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 quetiapine 25 \/ 100 \/ 200 mg (immediate-release)<\/strong> from a WHO-GMP certified manufacturer (Sun Pharma) — an atypical antipsychotic<\/strong> with broad use across schizophrenia, bipolar disorder, and treatment-resistant depression. Mechanism: D2 + 5-HT2A<\/sub> antagonism plus prominent H1<\/sub> antihistamine action (heavy sedation) plus alpha-1 blockade (orthostasis). Doses span a huge range by indication: 25–100 mg HS<\/strong> (off-label insomnia, anxiety adjunct — controversial), 300–800 mg\/day<\/strong> (schizophrenia, bipolar mania), 150–300 mg\/day<\/strong> (bipolar depression, MDD adjunct). Major class warnings<\/strong>: metabolic syndrome (weight, glucose, lipids — class effect), heavy sedation, orthostatic hypotension, QT prolongation, EPS (lower than first-generation antipsychotics), and FDA black box for elderly dementia mortality<\/strong>.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n<\/div>\n

Important — this is not a situational-anxiety medication.<\/strong> Psyquit is a atypical antipsychotic<\/strong>, prescribed and titrated over weeks for schizophrenia, bipolar mania and depression, bipolar maintenance, and adjunctive treatment of major depressive disorder<\/strong>. It is \u03b4\u03b5\u03bd<\/strong> the right drug for acute, performance-related anxiety (flying, public speaking, exams) — for those use cases beta-blockers (propranolol), benzodiazepines, or hydroxyzine are clinically appropriate. If you do not have a diagnosed mood, anxiety, or psychiatric disorder, do not start this medication.<\/div>\n
FDA black-box warning — elderly dementia mortality.<\/strong> All antipsychotics (atypical and conventional) carry an FDA black-box warning for increased mortality when used to treat dementia-related psychosis or behavioural disturbance in elderly patients. This medication is not approved<\/strong> for dementia-related symptoms.<\/div>\n

What Is Psyquit?<\/h2>\n

Psyquit is an oral immediate-release tablet of quetiapine fumarate 25 \/ 100 \/ 200 mg<\/strong> manufactured by Sun Pharma. Quetiapine (US brand Seroquel IR \/ Seroquel XR<\/strong>) is an atypical (second-generation) antipsychotic launched by AstraZeneca in 1997. It is a D2<\/sub> and 5-HT2A<\/sub> antagonist with strong H1<\/sub> antihistamine and moderate alpha-1 antagonist activity<\/strong>. The H1<\/sub> blockade drives the prominent sedation; the alpha-1 blockade drives orthostatic hypotension; the 5-HT2A<\/sub> antagonism reduces extrapyramidal side-effect risk compared with first-generation antipsychotics.<\/p>\n

\u03a4\u03bf IR (immediate-release)<\/strong> formulation reaches peak plasma in 1–2 hours, producing prompt sedation. Dose timing matters — sedation 1–3 hours after the dose can be either useful (insomnia adjunct) or limiting (daytime fatigue).<\/p>\n

\u0395\u03b3\u03ba\u03b5\u03ba\u03c1\u03b9\u03bc\u03ad\u03bd\u03b5\u03c2 \u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/h2>\n
    \n
  • Schizophrenia<\/strong> — acute and maintenance<\/li>\n
  • Bipolar mania<\/strong> — acute (monotherapy or with lithium \/ valproate)<\/li>\n
  • Bipolar depression<\/strong> — one of the few drugs FDA-approved for this; first-line in bipolar I depression<\/li>\n
  • Bipolar maintenance<\/strong> — with lithium or valproate<\/li>\n
  • Adjunctive treatment of MDD<\/strong> — XR formulation, 150–300 mg\/day with an antidepressant<\/li>\n
  • Off-label: insomnia (low dose 25–50 mg), anxiety (controversial — metabolic risk for non-psychotic anxiety), agitation in dementia (used with caution given black-box warning)<\/li>\n<\/ul>\n

    \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7 \u03b1\u03bd\u03ac \u03ad\u03bd\u03b4\u03b5\u03b9\u03be\u03b7<\/h2>\n\n\n\n\n\n\n\n\n\n\n
    \u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u039e\u03b5\u03ba\u03b9\u03bd\u03ae\u03c3\u03c4\u03b5<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n\u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
    Schizophrenia (IR)<\/td>\n50 mg BID<\/td>\n400–800 mg\/day<\/td>\n800 mg\/day<\/td>\nTitrate over 4–7 days; XR allows once-daily HS dosing<\/td>\n<\/tr>\n
    Bipolar mania (acute)<\/td>\n100 mg\/day × day 1, increase by 100 mg\/day<\/td>\n400–800 mg\/day<\/td>\n800 mg\/day<\/td>\nRapid titration to control mania<\/td>\n<\/tr>\n
    Bipolar depression<\/td>\n50 mg HS × day 1, then 100, 200, 300<\/td>\n300 mg\/day at bedtime<\/td>\n300 mg\/day<\/td>\nStandard maximum for this indication<\/td>\n<\/tr>\n
    MDD adjunct (XR only)<\/td>\n50 mg HS<\/td>\n150–300 mg\/day<\/td>\n300 mg\/day<\/td>\nAdd to existing antidepressant; sedation often dose-limiting<\/td>\n<\/tr>\n
    Off-label insomnia<\/td>\n25–50 mg HS<\/td>\n25–50 mg HS<\/td>\n100 mg HS<\/td>\nControversial — metabolic risk for sleep dose makes this a poor first choice; reserve for patients who have failed multiple alternatives<\/td>\n<\/tr>\n
    \u0397\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03b9<\/td>\n25–50 mg\/day, slower titration<\/td>\n\u2014<\/td>\nConsider 200–300 mg\/day max<\/td>\nGreater sedation and orthostasis — falls risk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    \u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n

    Side-effect profile by mechanism<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Mechanism<\/th>\nEffects<\/th>\nNotes \/ management<\/th>\n<\/tr>\n<\/thead>\n
    Metabolic (5-HT2C<\/sub> + H1<\/sub> appetite drive)<\/td>\nWeight gain (often significant), increased blood glucose \/ new-onset diabetes, dyslipidaemia<\/td>\nClass warning — baseline weight, BP, fasting glucose, lipids; reassess at 3 months and annually<\/td>\n<\/tr>\n
    H1<\/sub> blockade<\/td>\nHeavy sedation, drowsiness<\/td>\nUseful at bedtime; often limiting during the day. Less peak sedation with XR<\/td>\n<\/tr>\n
    Alpha-1 blockade<\/td>\n\u039f\u03c1\u03b8\u03bf\u03c3\u03c4\u03b1\u03c4\u03b9\u03ba\u03ae \u03c5\u03c0\u03cc\u03c4\u03b1\u03c3\u03b7, \u03b6\u03ac\u03bb\u03b7<\/td>\nSlow titration; check lying \/ standing BP<\/td>\n<\/tr>\n
    Anticholinergic (mild)<\/td>\nDry mouth, constipation<\/td>\nLess than olanzapine<\/td>\n<\/tr>\n
    D2<\/sub> blockade<\/td>\nExtrapyramidal symptoms (akathisia, parkinsonism, dystonia)<\/td>\nLower than first-generation antipsychotics; akathisia at higher doses<\/td>\n<\/tr>\n
    \u0386\u03bb\u03bb\u03bf<\/td>\n\u0395\u03c0\u03ad\u03ba\u03c4\u03b1\u03c3\u03b7 QT<\/td>\nBaseline ECG; caution with other QT-prolonging drugs<\/td>\n<\/tr>\n
    \u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nTardive dyskinesia<\/td>\nLower risk than typical antipsychotics but real with long-term use<\/td>\n<\/tr>\n
    \u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nNeuroleptic malignant syndrome<\/td>\nHyperthermia, rigidity, autonomic instability — emergency<\/td>\n<\/tr>\n
    \u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nHyperprolactinaemia<\/td>\nLess than risperidone<\/td>\n<\/tr>\n
    \u03a3\u03c0\u03ac\u03bd\u03b9\u03b5\u03c2<\/td>\nCataracts<\/td>\nLens monitoring controversial; some clinicians order 6-monthly slit-lamp exam<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    \u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n

    CYP3A4 substrate<\/strong>: levels rise with strong inhibitors (ketoconazole, ritonavir, clarithromycin) — reduce dose. Levels fall with strong inducers (rifampin, phenytoin, carbamazepine) — loss of efficacy.<\/p>\n

    Additive sedation<\/strong>: alcohol, benzodiazepines, opioids, sedating antidepressants.<\/p>\n

    \u0395\u03c0\u03ad\u03ba\u03c4\u03b1\u03c3\u03b7 QT<\/strong>: caution with citalopram (high dose), methadone, ondansetron, fluoroquinolones, ziprasidone.<\/p>\n

    \u0391\u03bd\u03c4\u03b9\u03c5\u03c0\u03b5\u03c1\u03c4\u03b1\u03c3\u03b9\u03ba\u03ac<\/strong>: additive orthostasis with alpha-blockers, ACE inhibitors, diuretics.<\/p>\n

    Anticholinergic burden<\/strong>: additive with diphenhydramine, oxybutynin.<\/p>\n

    Metabolic Monitoring<\/h2>\n

    All atypical antipsychotics carry a class warning for metabolic syndrome — weight gain, dyslipidaemia, and impaired glucose tolerance. Quetiapine sits in the higher-risk group (with olanzapine and clozapine). Standard monitoring: baseline + 3 months + annually<\/strong>: weight \/ BMI, waist circumference, fasting glucose or HbA1c, fasting lipid panel, blood pressure. Consider a switch to a lower-metabolic-risk agent (aripiprazole, lurasidone, ziprasidone) if weight \/ glucose deteriorates.<\/p>\n

    \u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n

    How long does Psyquit take to work?<\/h3>\n

    Acute psychosis or mania symptoms often respond within days; full benefit at 4–6 weeks. Bipolar depression response typically appears at 1–3 weeks at the 300 mg target.<\/p>\n

    Why is Psyquit used for sleep?<\/h3>\n

    Quetiapine 25–50 mg HS produces heavy sedation through H1<\/sub> blockade. Off-label sleep use has become widespread but is controversial — metabolic side effects accumulate even at low dose, and safer hypnotics exist.<\/p>\n

    Will Psyquit make me gain weight?<\/h3>\n

    Likely yes — quetiapine is one of the more weight-gain-prone atypicals. Average weight gain at therapeutic doses is 4–7 kg over 12 months; some patients gain considerably more. Lifestyle interventions help; switching to aripiprazole or lurasidone may be needed if weight becomes problematic.<\/p>\n

    Is Psyquit safe in elderly patients with dementia?<\/h3>\n

    FDA black-box warning for increased mortality in elderly with dementia-related psychosis or behavioural disturbance. Use only when behavioural and non-pharmacological strategies have failed and the symptoms are severe; lowest dose, shortest duration, with informed consent of family.<\/p>\n

    Can I drink alcohol on Psyquit?<\/h3>\n

    Avoid — additive sedation and orthostasis. Even moderate alcohol substantially increases sedation and falls risk.<\/p>\n

    What is the difference between IR and XR quetiapine?<\/h3>\n

    IR peaks at 1–2 hours; XR peaks at ~6 hours and allows once-daily dosing. IR has more peak sedation just after the dose; XR has a smoother profile. Daily AUC is similar at equivalent doses.<\/p>\n

    Will Psyquit cause extrapyramidal side effects?<\/h3>\n

    Quetiapine has the lowest EPS risk among atypicals along with clozapine. Akathisia at higher doses is the most common motor side effect; tardive dyskinesia risk exists with long-term use but is much lower than first-generation antipsychotics.<\/p>\n

    Is Psyquit safe in pregnancy?<\/h3>\n

    Limited data — quetiapine is one of the better-studied atypicals in pregnancy. Continuation is reasonable when needed for serious mental illness; first-trimester exposure does not appear to increase major malformation rates above baseline.<\/p>\n

    Can I stop Psyquit abruptly?<\/h3>\n

    Better to taper, especially after long-term use — abrupt discontinuation can produce withdrawal dyskinesia, insomnia, nausea, sweating, and rebound psychosis or mania. Reduce by 25–50 mg every 1–2 weeks.<\/p>\n

    How should Psyquit be stored?<\/h3>\n

    Store at 15–30 °C in the original blister packaging, away from moisture and sunlight. Keep out of reach of children.<\/p>\n

    \u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u03b1\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u03b5\u03c5\u03b8\u03cd\u03bd\u03b7\u03c2:<\/strong> Information on this page is intended for adults using prescribed psychiatric medication and is not a substitute for individualised medical care. Antidepressants, antipsychotics, and related medications can interact with other drugs, alcohol, and pre-existing conditions. Discuss any new medication, dose change, or planned discontinuation with a qualified prescriber. If you experience suicidal thoughts, mania, severe akathisia, signs of serotonin syndrome (high fever, confusion, muscle rigidity, rapid heart rate), or neuroleptic malignant syndrome, seek emergency care immediately.<\/div>\n

    <\/p>\n

    \u03a3\u03c7\u03b5\u03c4\u03b9\u03ba\u03ad\u03c2 \u0395\u03bd\u03b1\u03bb\u03bb\u03b1\u03ba\u03c4\u03b9\u03ba\u03ad\u03c2<\/h3>\n

    \u0386\u03bb\u03bb\u03b1 \u03c0\u03c1\u03bf\u03ca\u03cc\u03bd\u03c4\u03b1 \u03c3\u03b5 \u03a7\u03c1\u03cc\u03bd\u03b9\u03b5\u03c2 \u03a0\u03b1\u03b8\u03ae\u03c3\u03b5\u03b9\u03c2<\/strong> \u03c0\u03bf\u03c5 \u03bf\u03b9 \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 \u03b5\u03be\u03b5\u03c4\u03ac\u03b6\u03bf\u03c5\u03bd \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/p>\n